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AnAlySiS Of COSt-EffECtivEnESS Of USE Of tOriC intrAOCUlAr lEnSES 
COmPArEd With trAditiOnAl mOnOfOCAl lEnSES in PAtiEntS With 
CAtArACtS And PrE-ExiSting COrnEAl AStigmAtiSm
Ochoa F.1, Simbaqueba E.2, Romero M.2, Lopez A.3
1Salutia Foundation, Bogota, Colombia, 2Fundacion Salutia, Bogota, Colombia, 3Alcon, Bogota, 
Colombia
Objectives: evaluate the cost-effectiveness of the use of toric intraocular lenses 
(IOLs) in surgery of patients with cataract and preexisting corneal astigmatism (> 
0.75 D), versus the use of traditional monofocal intraocular lenses (IOLs) from the 
perspective of third party payer, as a way to define which technology could consid-
ered in the health care reimbursement. MethOds: in a decision tree type model 
was simulated the cataracts surgery intervention in a time horizon of five years. The 
outcome measure was the cumulative visual acuity of 20/32, which was expressed 
in normal vision time without additional support. The drug costs were taken from 
SISMED (2013), the costs from multi-core procedures of the health ministry (SISPRO), 
the cost of glasses and contact lenses from commercial channel, and the cost of 
IOLs were taken as the selling price of Alcon Laboratories. Finally a Montecarlo type 
sensitivity analysis was performed. Results: as primary outcome, time normal 
distance vision without additional support was higher with toric IOLs, which it were 
more effective at 3,64 years versus 2,97 years achieved with traditional monofocal 
IOLs. Intervention with toric IOLs showed in the time horizon of five years be more 
expensive with (USD) $1.093,55 versus costs of traditional monofocal IOLs (USD) 
$732,71. In this regard cataract surgery is more effective and more costly with toric 
IOLs than with traditional monofocal IOLs with an incremental cost-effectiveness 
ratio of (USD) $534,83 per each year of normal vision without additional support. It 
was observed that the ICER improves if there is a greater visual impairment due to 
astigmatism before surgery, as well, to diopters < 1.50, > 1.50 < 2.00 and > 2.00 the ICER 
was (USD) $ 712.40, (USD) $ 416.75 and (USD) $ 382.16 respectively. cOnclusiOns: 
toric IOLs proved to be cost-effective for the treatment of patients with cataract 
and preexisting astigmatism.
PSS20
COSt-EffECtivEnESS Of rAnibizUmAb vErSUS lASEr in thE trEAtmEnt Of 
viSUAl imPAirmEnt dUE tO diAbEtiC mACUlAr OEdEmA (dmE) frOm thE 
COlOmbiAn hEAlth CArE SyStEm PErSPECtivE
Karpf Benavides E., Escobar L.M., Naranjo J.
Novartis, Bogotá, Colombia
Objectives: To evaluate the cost effectiveness, from the Colombian health care 
system perspective, of ranibizumab monotherapy or ranibizumab combined with 
laser against laser monotherapy for the treatment of diabetic macular edema 
(DME). MethOds: A Markov model was designed to simulate the clinical and eco-
nomic benefits associated with ranibizumab as either monotherapy or combined 
with laser versus laser monotherapy in the treatment of visual impairment due 
to DME. The effectiveness outcomes measured were the life years without visual 
impairment based on RESTORE 3-year follow-up data. Over 15-year time horizon 
annual cycles were performed. The costs involved in the model were taken from 
the official medication cost database in Colombia (SISMED) and 6 Colombian health 
care providers (IPS) The analysis, according to the RESTORE study, considered that 
22 % of patients received treatment on both eyes. For ranibizumab and laser group, 
the first three years transition probabilities where taken from the same study and 
for the laser group the second and third year data was taken from the Diabetic 
Retinopathy Clinical Research Network (DRCR.net ). Results: Ranibizumab mono-
therapy showed a gain of 0.30 years with no visual impairment at an incremental 
cost of COP 8, 272, 248 (USD 4.273,01) relative to laser monotherapy, resulting in 
an incremental cost- effectiveness ratio (ICER) of COP 28,041,494 (USD $14.484,77). 
Likewise ranibizumab monotherapy was superior to combination therapy with an 
ICER of COP 34,224,675 (USD $17.678, 67) in a time horizon of 15 years. Probabilistic 
sensitivity analysis placed ranibizumab monotherapy as a more cost-effective alter-
native versus laser monotherapy in 95% of the cases. cOnclusiOns: The results 
pointed out that ranibizumab both as a monotherapy as well as combined with 
laser therapy are cost-effective alternatives from the Colombian health care system 
perspective.
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USing A CrOSSOvEr StUdy dESign fOr EArly hOSPitAl-bASEd hEAlth 
tEChnOlOgy ASSESSmEnt: thE COSt-EffECtivEnESS Of CliniC-bASEd 
ChlOrAl hydrAtE SEdAtiOn vErSUS gEnErAl AnAESthESiA fOr 
PAEdiAtriC OPhthAlmOlOgiCAl PrOCEdUrES
Burnett H.F., Lambley R., West S., Mireskandari K., Ungar W.J.
Hospital for Sick Children, Toronto, ON, Canada
Objectives: Hospitals are a favorable environment for early health technology 
assessment (HTA) and cross-over designs are ideally suited for this. For example, 
young children who cannot tolerate eye examinations may require examination 
under anesthesia (EUA) in an operating room. Examination under chloral hydrate 
sedation (EUS) in an outpatient clinic may be a convenient and cost-effective 
alternative. The objective was to determine the incremental cost of EUS com-
pared to EUA per additional successful procedure gained from a societal perspec-
tive. MethOds: A cost-effectiveness analysis was conducted using a retrospective 
cross-over cohort of 80 children that had both EUS and EUA. Direct costs included 
health professional services, supplies and equipment and indirect costs included 
parent productivity losses. Outcomes included the number of successful proce-
dures and adverse events (AEs). One-way and probabilistic sensitivity analyses 
were conducted. Results: The mean cost per patient was $406 (95% CI $401, 
$411) for EUS and $1,135 (95% CI $1,125, $1,145) for EUA. The mean number of 
successful procedures per patient was 1.39 (95% CI 1.34, 1.42) for EUS and 2.06 
(95% CI 2.02, 2.11) for EUA. EUS was $729 less costly on average than EUS but 
resulted in 0.68 fewer successful procedures per child. Three AEs occurred in 2 
EUS patients compared to 1 in the EUA group. The result was robust to varying 
Objectives: Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral 
retinal degeneration. RP is a leading cause of blindness resulting in incurable visual 
impairment and drastic reduction in the Quality of life of the patients. Although the 
condition is at present incurable, advances in the field of retinal implants demonstrate 
the progress now being made in combating the condition and restoring a measure of 
sight to those afflicted. The objective of this study was to assess the cost-effectiveness 
of first ever-commercial implant intended to restore some vision in the Retinitis 
Pigmentosa (RP) patients. MethOds: A multi -state transition Markov model was 
developed to determine the cost-effectiveness of retinal transplant versus usual care 
in RP from the perspective of health care payer. A hypothetical cohort of 1000 RP 
patients aged 46 years followed up over a (lifetime) 25-year time horizon. Health 
outcomes were expressed as quality adjusted life years (QALYs) and direct health care 
costs expressed in 2012 € . Results are reported as incremental cost per ratios (ICERs) 
with outcomes and costs discounted at an annual rate of 3.5%. Results: The ICER for 
the retinal implant was € 14,603 /QALY. Taking into account the uncertainty in model 
inputs the ICER was € 14,482/QALY in the probabilistic analysis. In the scenarios of 
an assumption of no reduction on cost across model visual acuity states or a model 
time horizon as short as 10 years the ICER increased to € 31,890/QALY and € 49,769/
QALY respectively. cOnclusiOns: This economic evaluation shows that the retinal 
implant is a cost-effective intervention compared to usual care of the RP patients. 
The ICER for retinal implant falls below the published societal willingness to pay 
of EuroZone countries. Retinal implants could eventually change the lives of up to 
200,000 people worldwide who suffer from blindness due to Retinitis Pigmentosa.
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COSt-EffECtivEnESS AnAlySiS Of OPhthAlmiC PrOStAglAndin 
AnAlOgUES fOr thE mAnAgEmEnt Of OCUlAr hyPErtEnSiOn And 
glAUCOmA
Lin L., Zhao Y.J., Khoo A.L., Teng M., Lim B.P.
Pharmacy & Therapeutics Office, Corporate Development, National Healthcare Group, Singapore, 
Singapore
Objectives: Prostaglandin analogues (PGAs) lower ophthalmic intraocular pres-
sure (IOP) and are widely used as first-line therapies in the management of ocular 
hypertension (OH) or primary open-angle glaucoma (POAG). They are more costly 
than alternative agents and this may impose a financial burden on patients as 
treatment is life-long. This study sought to evaluate the cost-effectiveness of four 
PGAs, bimatoprost, latanoprost, tafluprost and travoprost, as first-line monotherapy 
in patients with OH or POAG to inform formulary decision on the optimal agents to 
stock in a local hospital. MethOds: A decision-analytic model was developed to 
simulate a cohort of patients with OH or POAG receiving PGA or timolol treatment 
over a one-month time horizon. The effectiveness data used were the proportion of 
patients achieving a clinical target of at least a 30% reduction in IOP from baseline 
and the incidence of hyperemia, a common side effect of PGAs. Treatment success 
and hyperemia rates were extracted from published literature and synthesised 
using a network meta-analysis. Cost of medications and doctor visits were included, 
in accordance with the adopted patient’s perspective, and this information was 
obtained from the hospital. The results were expressed as incremental cost per 
additional patient achieving clinical success. Deterministic sensitivity analyses 
were conducted to assess the robustness of the results. Results: Latanoprost and 
bimatoprost had a positive incremental cost-effectiveness ratio (ICER) of SGD 168 
and SGD 200, respectively, relative to timolol. Both travoprost and tafluprost were 
dominated by latanoprost. The results were most sensitive to the proportion of 
patients achieving at least a 30% IOP reduction from baseline and the cost of medica-
tions. cOnclusiOns: This analysis suggests that latanoprost and bimatoprost are 
preferred among the four PGAs in terms of cost-effectiveness. Cost-effectiveness 
should be considered alongside other factors including comparative clinical efficacy 
and safety to make an informed formulary decision.
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COSt-EffECtivEnESS AnAlySiS Of inSUrEd EyE CArE SErviCES by 
OPtOmEtriStS in PrinCE EdWArdS iSlAnd (PEi): An ExAmPlE Of diAbEtiC 
rEtinOPAthy mAnAgEmEnt
Tu H.A.T., Wedge R., Yaping J., Trope G., El-Defrawy S., Flanagan J., Buys Y.M., Thavorn K.
University of Toronto, Toronto, Canada
Objectives: Optometric services are not publicly funded in Prince Edward Island 
(PEI). This analysis aimed to assess the cost-effectiveness of funding optometrists 
for diabetic eye care versus funding general practitioners (GPs) for such services in 
PEI using PEI government’s health care payer perspective. MethOds: A Markov 
cohort model of diabetic retinopathy (DR) was developed using PEI disease data 
(diabetic incidence, DR incidence and mortality), PEI cost data, and the data from 
the literature (utilities, DR progression). In the base-case, biannual screening of 
DR was assumed. A hypothetical cohort of diabetic patients of 35 years and older 
in PEI (8,392) was simulated to estimate expected lifetime health outcomes (non-
proliferative cases, proliferative cases, mortality, quality-adjusted life years (QALYs)) 
and cost (screening cost, treatment of proliferation retinopathy). Primary outcomes 
were expected QALYs, cost and incremental cost per QALY gained. Sensitivity analy-
ses were conducted to examine the robustness of the results. QALYs and costs were 
discounted at 5%. Results: In the base-case, biannual screening and treatment of 
DR by optometrists was determined as a cost-saving strategy compared to GP deliv-
ered service. The model was most sensitive to the health utility of diabetic patients, 
and screening rates provided by GPs. Varying the discount rate from 0 to 5% had 
the least impact on the cost-effectiveness of screening results. In other screening 
scenarios (annual and biennial), services provided by optometrists appeared to be 
very cost-effective, or even cost-savings compared to services delivered by GPs. The 
estimated potential financial savings to PEI government could be between Canadian 
dollar (C$) 45,000 to C$390,000 during 1 year to 10-year horizon if optometric services 
were publicly funded. cOnclusiOns: Publicly funded screening and treatment 
of DR by optometrists in PEI is potentially a cost-saving strategy compared to the 
usual care provided by GPs.
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scheduled for an office visit within the next 3 weeks for an anti-VEGF injection or 
monitoring. Additionally, a survey was administered to 75 patients with NVAMD 
who were aged ≥ 50 years and had received ≥ 1 anti-VEGF injection in the past 
6 months. Furthermore, telephone interviews were conducted with 13 caregivers 
of patients with NVAMD. Results: 56 physicians provided data for 221 patients 
with NVAMD. Management of patients with NVAMD comprised 20% of the health 
care staff’s working week, with an average of 24 staff members involved. An aver-
age patient visit for management of NVAMD was 90 minutes (range: 13 minutes 
to > 4 hours). Patients reported an average time commitment per visit of almost 
12 hours, including preappointment preparation (16 minutes), travel (66 minutes), 
waiting time (37 minutes), treatment time (43 minutes), and recovery (9 hours). 
Caregivers reported taking time away from work (> 20%) and personal activities (> 
25%) to accompany patients to appointments. cOnclusiOns: NVAMD manage-
ment imposes a substantial time burden on physicians and other staff members, 
as well as patients and caregivers. There may be a need for additional support and/
or reimbursement for services required by patients and caregivers, as well as those 
provided by physicians.
SEnSOry SyStEmS diSOrdErS – Patient-reported Outcomes & Patient Prefer-
ence Studies
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PAtiEnt AdhErEnCE And nOn-PErSiStEnCE bEhAviOUr in rEAl lifE 
ACtiniC KErAtOSiS (AK) tOPiCAl trEAtmEnt in thE UK, gErmAny And 
frAnCE
Erntoft S.1, Norlin J.1, Pollard C.2, Diepgen T.L.3
1LEO Pharma A/S, Ballerup, Denmark, 2Adelphi Values, Bollington, UK, 3University Heidelberg, 
Heidelberg, Germany
Objectives: To gain an understanding of the use of self-administered topical 
therapies for actinic keratosis exploring patients’ persistence and adherence 
behaviour. MethOds: The study was conducted as an online longitudinal ques-
tionnaire-based survey in the UK, France and Germany between October 2012 
and May 2013, among AK patients diagnosed and recruited by a physician +/- one 
week from any topical therapy initiation. The study design consisted of a base-
line questionnaire followed by up to 6 follow-up questionnaires, completed at 
fortnightly intervals to cover a full treatment course. Persistence was calculated 
as persistence % = (Actual days of use/Advised days of use) x 100 and Adherence 
as Adherence % = (Actual times of use/Advised times of use) x 100, both were 
calculated using thresholds of 100% and 80%. Logistic regression modelling (mul-
tivariate analysis) was also performed to investigate causes of non-adherence/
persistence among the patients. Results: Overall, 224 patients completed the 
baseline questionnaire. Over 50% of the sample were prescribed diclofenac sodium 
at baseline, the remaining patients had been prescribed any of imiquimode 5 % 
or 3,75%, fluorouracil, or fluorouracil + salicylicacid. Over the course of the study 
approximately 2/3 of the patients remained on the same therapy from baseline to 
the end of the study and 1/3 ceased therapy or switched at least once. The majority 
of cases occurred on instruction from a health care professional (HCP). Of those 
who ceased or switched therapy, 79-94% of patients being non-persistent to their 
prescribed treatment duration, however, over 90% of patients were reported to 
be adherent to application. Controlled for treatment, gender and quality of life, 
patients aged > 60 years were significantly more adherent compared to patients 
aged < 60 years. cOnclusiOns: This study reports that 1/3 of topical AK patients 
switch or prematurely stop treatment suggesting that patients experience issues 
preventing completion of treatment course.
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ExAmining PAtiEnt PrOvidEr COmmUniCAtiOn rEgArding COSt in thE 
glAUCOmA PAtiEnt POPUlAtiOn
Slota C.1, Blalock S.1, Carpenter D.2, Robin A.3, Muir K.4, Sleath B.1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2University of North Carolina 
at Asheville, Asheville, NC, USA, 3University of Maryland and Johns Hopkins University, 
Baltimore, MD, USA, 4Duke University, Durham, NC
Objectives: Adherence to medications is a significant problem in glaucoma 
patients. Costs of medications have frequently been cited as barriers to adherence. 
This study aims to identify the extent of physician-patient communication concern-
ing medication cost during glaucoma medical visits. The study also aims to examine 
ophthalmologist and patient characteristics that influence whether the ophthal-
mologist discusses medication costs with the patient during glaucoma medical 
visits. MethOds: English-speaking adults with glaucoma and their ophthalmolo-
gists at six geographically diverse ophthalmology practices were recruited for the 
study. All visits were videotape recorded and transcribed verbatim. Patients were 
interviewed following their office visit. A research assistant reviewed the patient’s 
medical records noting comorbidities, glaucoma medication use, and glaucoma 
severity. Ophthalmologists completed a demographic survey. Transcripts were 
coded to identify whether the ophthalmologist discussed medication cost with 
the patient during the office visit. Bivariate analyses were performed to examine 
whether ophthalmologist and patient characteristics were associated with discus-
sion of medication cost. Results: Fifteen ophthalmologists and 279 of their glau-
coma patients participated in the study. Ophthalmologists discussed medication 
costs during only 67 (24%) of glaucoma medical visits. Ophthalmologists with more 
years of experience practicing were significantly more likely to discuss medica-
tion cost (p< 0.03). Also, ophthalmologists were significantly more likely to discuss 
medication cost with patients who had higher levels of formal education, were new 
to using glaucoma medications, and were taking more glaucoma medications (p< 
0.05). cOnclusiOns: Ophthalmologists do not routinely discuss medication cost 
during glaucoma patient office visits. Future research is needed to investigate the 
impact of physician-patient communication concerning medication cost on adher-
ence in the glaucoma patient population.
the cost assumptions. When failed EUS were assumed to be completed as EUA, 
the mean cost of EUS increased to $586 (95% CI $438, $735), but remained signifi-
cantly less than EUA. cOnclusiOns: Hospitals pressured to rationalize care cre-
ate opportunities for early HTA. Cross-over designs are promising for assessments 
of costs and effectiveness of emerging technologies because patients serve as their 
own control. This study demonstrated significant savings when ophthalmologic 
exams were carried out in a hospital outpatient clinic, albeit with slightly fewer 
procedures completed.
PSS22
OCriPlASmin fOr thE trEAtmEnt Of vitrEOmACUlAr trACtiOn And 
mACUlAr hOlES: lOng-tErm mOdElling Of CliniCAl And ECOnOmiC 
vAlUE Of rESOlUtiOn Of trACtiOn in frAnCE
Moro L.1, Bennison C.2, Thurston S.2, Lescrauwaet B.3
1ThromboGenics NV, Heverlee, Belgium, 2Pharmerit Ltd, York, UK, 3Xintera Ltd., London, UK
Objectives: Persistent attachment between the vitreous and the macula causes 
vitreomacular traction (VMT) and subsequent formation of a macular hole (MH) 
leading to symptomatic loss of visual function. This analysis estimated long-term 
benefits and costs associated with the resolution of traction following treatment 
with ocriplasmin versus standard-of-care (observation, followed by vitrectomy if 
needed), in the French health care system, from a collective perspective. MethOds: 
The model included (1) a short-term decision-tree, simulating 6-month anatomi-
cal and visual outcomes observed in the two Phase III MIVI-TRUST ocriplasmin 
randomized controlled trials (RCTs), and (2) a long-term Markov state-transition 
model, tracking patients over a lifetime-period. Both models were linked through 
common health states based on VMT resolution or MH closure, number of vitrec-
tomies and visual acuity status. Effectiveness and safety outcomes were based on 
the MIVI-TRUST RCTs. Patient populations included (1) total licensed VMT popula-
tion, independent of the presence/absence of a MH, and two subgroups according 
to pre-specified analyses (2) VMT with epiretinal membrane (ERM), and (3) VMT 
without ERM. Benefit was measured in quality-adjusted life years (QALYs), based 
on (1) time spent in health states defined by the visual acuity of the best and worse 
seeing eye, (2) disutility impact associated with surgical interventions (vitrectomy 
and cataract), adverse events and metamorphopsia. Resources used with ocriplas-
min and standard-of-care were based on expert opinions. Unit costs were mainly 
drawn from the French national hospital database. Results: Over a life-time, ocri-
plasmin versus standard-of-care generated incremental benefits in terms of QALYs 
and overall treatment costs in group (1) 0.071; € 2,107 (2) 0.034; € 2,689, and (3) 0.093; 
€ 1,757. Lifetime per-patient cost/QALY was € 29,767; € 78,393, and € 18,917, respec-
tively. cOnclusiOns: Applying commonly accepted cost-effectiveness thresholds 
(€ 35,000-€ 50,000/QALY), this first French cost-utility analysis shows that ocriplasmin 
represents a cost-effective strategy in total licensed VMT population, and particu-
larly in patients without ERM.
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COSt Utility AnAlySiS Of AflibErCEPt, rAnibizUmAb, And bEvACizUmAb 
fOr thE trEAtmEnt Of nEOvASCUlAr AgE-rElAtEd mACUlAr 
dEgEnErAtiOn
Lin C.W., Hay J.
University of Southern California, Los Angeles, CA, USA
Objectives: To evaluate the cost-effectiveness of intravitreal aflibercept compared 
with ranibizumab and bevacizumab for wet age-related macular degeneration 
(AMD) patients. MethOds: A Markov model was applied in cost-utility analysis to 
evaluate the incremental cost-effectiveness ratio (ICER) between aflibercept, ranibi-
zumab, and bevacizumab from societal perspective over 12 years. Patients switched 
to as-needed based dosing after one year on the FDA approved regimens. Yearly 
transitional probabilities were obtained and extrapolated from two-year randomized 
control trials. Direct medical costs, resource utilization and utility scores were esti-
mated and calculated using the Medicare National Physician Fee Schedule and other 
published studies. Costs were adjusted and reported in 2013 US dollar. Base case 
was a 78 year-old patient with vision acuity at 60-letter level. The cost-effectiveness 
threshold was $ 51,749, as three-fold GDP per capita in 2013. One-way sensitivity 
analyses were performed to test for the robustness of the model. Results: The 
cost-effectiveness ratio (CER) for aflibercept, ranibizumab, and bevacizumab were 
$31,404, $34,888, 43,096, respectively. The ICER for aflibercept was dominant com-
pared to both ranibizumab and bevacizumab. When caregiver costs were excluded, 
bevacizumab became the cost-effective treatment (dominated by ranibizumab; the 
ICER for aflibercept was $73,625). The number of as-needed doses, instruments 
used for obtaining utility, initial level of vision acuity level and variation in drug 
costs demonstrated small impact on relative cost-effectiveness. cOnclusiOns: 
Aflibercept was the cost-effective treatment for AMD patients compared to ranibi-
zumab and bevacizumab from societal perspective.
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bUrdEn Of illnESS in thE mAnAgEmEnt Of AgE-rElAtEd mACUlAr 
dEgEnErAtiOn: findingS frOm A timE-And-mOtiOn StUdy
Williams Z.Y.1, Prenner J.L.2, Halperin L.S.3, Hogue S.4, Seibert R.1
1Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA, 2Robert Wood Johnson Medical School, 
New Brunswick, NJ, USA, 3Charles E. Schmidt College of Medicine, Fort Lauderdale, FL, USA, 4RTI-
Health Solutions, Research Triangle Park, NC, USA
Objectives: Neovascular age-related macular degeneration (NVAMD) is a costly, 
debilitating, and progressive disease that profoundly impacts patients’ visual 
acuity. NVAMD is the leading cause of blindness in the developed world. This 
time-and-motion study investigated the physician, patient, and caregiver time 
burden associated with the management of patients with NVAMD in the United 
States. MethOds: Quantitative research was conducted in June 2011 and August 
2012. A survey was conducted with 57 retina specialists who administered ≥ 50 
vascular endothelial growth factor (VEGF)-inhibitor injections per month; 56 of 
these physicians completed records (patient history and diaries) for ≤ 5 patients 
